Anna Lis-Swiety

Publications of Anna Lis-Swiety

• Serum human cartilage glycoprotein-39 in patients with systemic sclerosis: relationship to skin and articular manifestation.

  Authors: Dominika Wcislo-Dziadecka, Anna Kotulska, Ligia Brzezińska-Wcislo, Malgorzata Widuchowska, Anna Lis-Swiety, Magdalena Kopec-Medrek, Eugene J Kucharz

  Clinical rheumatology. 08/2010; 29(8):933-5.

  Human cartilage glycoprotein-39 (HC gp-30) is a secretory protein of several types of cells including chondrocytes. It has been suggested to be a laboratory index of joint damage. Thirty-two patientsHuman cartilage glycoprotein-39 (HC gp-30) is a secretory protein of several types of cells including chondrocytes. It has been suggested to be a laboratory index of joint damage. Thirty-two patients with systemic sclerosis (SSc) and 22 age-matched controls were investigated. An increased serum HC gp-39 level was shown in SSc patients and was found to correlate with inflammatory indices. There was no correlation with modified Rodnan score, joint involvement, or duration of symptoms of SSc. The obtained results indicate for possible relationship of HCgp-39 to inflammation but do not suggest determination of HC gp-39 as clinically applicable index of articular involvement in SSc patients.

• Serum human cartilage glycoprotein-39 levels in patients with systemic lupus erythematosus.

  Authors: Dominika Wcisło-Dziadecka, Anna Kotulska, Ligia Brzezińska-Wcisło, Eugeniusz J Kucharz, Anna Lis-Swiety, Grazyna Kamińska-Wiciorek

  Polskie archiwum medycyny wewnȩtrznej. 12/2009; 119(12):777-84.

  INTRODUCTION: Human cartilage glycoprotein-39 (HC gp-39) is a protein secreted by various cells including chondrocytes. Serum HC gp-39 has been suggested to be a marker of cartilage damage. However,INTRODUCTION: Human cartilage glycoprotein-39 (HC gp-39) is a protein secreted by various cells including chondrocytes. Serum HC gp-39 has been suggested to be a marker of cartilage damage. However, inflammation involving other sites than the joints is an additional factor that increases the serum level of HC gp-39. OBJECTIVES: The aim of the study was to evaluate the usefulness of HC gp-39 determination in serum of patients with systemic lupus erythematosus (SLE) as a marker of joint involvement. PATIENTS AND METHODS: Serum HC gp-39 levels were measured in 25 patients with SLE and 22 healthy controls. SLE activity was assessed by the Systemic Lupus Erythematosus Disease Activity Index, and articular involvement by calculating the number of swollen and tender joints. The markers of inflammation (erythrocyte sedimentation rate, C-reactive protein) were determined. RESULTS: We observed an increase in HC gp-39 in SLE patients. However, there was no correlation of this parameter with disease activity, inflammatory markers (except serum gamma globulin levels), and articular involvement. CONCLUSIONS: The study suggests that increased HC gp-39 in SLE patients results mainly from inflammation and is not useful as a marker of joint involvement.

• [Diagnostic and therapeutic difficultes in pityriasis rubra pilaris--case report]

  Authors: Dominika Wcisło-Dziadecka, Ligia Brzezińska-Wcisło, Ewa Krauze, Anna Lis-Swiety

  Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego. 12/2005; 19(113):667-70.

  Pityriasis rubra pilaris Devergie is a very rare papulosquamosus disease which has chronic course and still unclear etiology. Already, we know that this dermatosis occurs as often in male as inPityriasis rubra pilaris Devergie is a very rare papulosquamosus disease which has chronic course and still unclear etiology. Already, we know that this dermatosis occurs as often in male as in female, can be present in each age and has genethics background. Diagnostic and especially therapy of those skin diseases is very difficult and can make a lot of problems not only dermatologist. This paper presents the case of a 48-year-old man with diagnosed and histological confirmed Pityriasis rubra pilaris Devergie. Advantages of retinoids therapy were also discussed.

• [Photodynamic therapy in dermatology]

  Authors: Anna Lis-Swiety, Ligia Brzezińska-Wcisło, Dominika Wcisło-Dziadecka, Grazyna Kamińska-Winciorek

  Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego. 04/2005; 18(105):354-7.

  Photodynamic therapy (PDT) is a therapeutic modality, in which the administration of a photosensitizing substances followed by selective irradiation of the lesion with visible light leads toPhotodynamic therapy (PDT) is a therapeutic modality, in which the administration of a photosensitizing substances followed by selective irradiation of the lesion with visible light leads to destruction of tissues. Authors provide the main principles, recent developments, indications and limitations for the use of PDT in the treatment of skin diseases.

• [Phototherapy in dermatology]

  Authors: Dorota Trzmiel, Ligia Brzezińska-Wcisło, Ewa Krauze, Anna Lis-Swiety

  Przegla̧d lekarski. 02/2005; 62(12):1552-5.

  Treatment of some skin diseases by exposure to ultraviolet radiation is presented. Phototherapy including radiation of different lenghts of waves has been used in medicine for along period of time,Treatment of some skin diseases by exposure to ultraviolet radiation is presented. Phototherapy including radiation of different lenghts of waves has been used in medicine for along period of time, it also plays an importaint role in modern dermatology. The study presents the modern methods of phototherapy and photochemiotherapy as well as history, indications, contraindications and side effects of phototherapy.